Core Viewpoint - The company is on track to complete the first patient dosing of its mRNA tumor vaccine within this year, focusing on glioblastoma and rhabdomyosarcoma indications [2] Company Progress - The company confirmed that the development of the mRNA vaccine is proceeding as planned and that the progress is in line with expectations [2] - Investors are encouraged to follow the company's official updates for further information on the vaccine's development [2]

Group 1 - The company Watson Bio is developing an mRNA vaccine for respiratory syncytial virus (RSV) in collaboration with partners [2] - The clinical research application for the RSV vaccine has been accepted as of August 2025 and is currently in the technical review stage [2]